Stockscreener 앱 받기
60.60
0.13%
-0.08
전일 마감가:
$60.68
열려 있는:
$60.72
하루 거래량:
1.20M
Relative Volume:
0.71
시가총액:
$11.74B
수익:
$4.08B
순이익/손실:
$32.48M
주가수익비율:
432.86
EPS:
0.14
순현금흐름:
$16.80M
1주 성능:
-2.13%
1개월 성능:
-17.19%
6개월 성능:
-7.94%
1년 성능:
+6.37%
1일 변동 폭
$60.35
$60.97
1주일 범위
$60.24
$63.31
52주 변동 폭
$50.35
$83.95
인사이트 코퍼레이션 Stock (INCY) Company Profile
명칭
Incyte Corp
전화
(302) 498-6700
주소
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
INCY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
60.60 | 11.74B | 4.08B | 32.48M | 16.80M | 0.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
인사이트 코퍼레이션 Stock (INCY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-18 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2025-03-18 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-12-17 | 개시 | UBS | Neutral |
| 2024-10-29 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-10-01 | 개시 | Wolfe Research | Outperform |
| 2024-09-18 | 다운그레이드 | Truist | Buy → Hold |
| 2024-07-02 | 다운그레이드 | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | 개시 | Deutsche Bank | Hold |
| 2024-04-23 | 개시 | Cantor Fitzgerald | Neutral |
| 2024-02-23 | 개시 | Jefferies | Buy |
| 2024-02-14 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-11-21 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-07-25 | 개시 | Citigroup | Buy |
| 2023-05-04 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-04-10 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | 업그레이드 | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | 개시 | Piper Sandler | Overweight |
| 2022-08-03 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-08-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-07-28 | 개시 | Wells Fargo | Equal Weight |
| 2022-02-09 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | 개시 | BMO Capital Markets | Market Perform |
| 2021-07-20 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-02-10 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | 개시 | Truist | Buy |
| 2021-01-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-06-16 | 개시 | The Benchmark Company | Hold |
| 2020-05-06 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-04-29 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | 재개 | William Blair | Outperform |
| 2020-03-13 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | 재개 | BofA/Merrill | Neutral |
| 2020-01-03 | 재확인 | BMO Capital Markets | Market Perform |
| 2020-01-03 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2020-01-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-10-03 | 개시 | Mizuho | Buy |
| 2019-09-12 | 개시 | BMO Capital Markets | Market Perform |
| 2019-09-05 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | 재개 | Morgan Stanley | Equal-Weight |
| 2019-09-05 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2019-05-21 | 개시 | Credit Suisse | Neutral |
| 2019-05-03 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2019-04-11 | 개시 | Stifel | Hold |
| 2019-04-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | 업그레이드 | William Blair | Mkt Perform → Outperform |
모두보기
인사이트 코퍼레이션 주식(INCY)의 최신 뉴스
Incyte Announces Positive Phase 3 Results for Hidradenitis Suppurativa Treatment - MSN
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch
Incyte Had a Bad Week. Investors Are Used to It. - MSN
Leerink Partners Adjusts Price Target on Incyte to $92 From $100, Maintains Outperform Rating - Marketscreener.com
Incyte’s Hold Rating: Balancing Pipeline Challenges and Established Product Valuation - TipRanks
Monday.com, Incyte, Lucid, Bloom, EQT: Trending by Analysts - TipRanks
Why Incyte Stock Was Tanking This Week - MSN
Incyte (INCY) Stock Declines Due to Clinical Trial Results - GuruFocus.com
The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics - Yahoo Finance
Incyte EVP Barry Flannelly sells $1.34 million in stock - Investing.com India
Stock market unimpressed by results for Incyte acne drug as share price drops 11% - delawarebusinessnow.com
Incyte price target lowered to $72 from $74 at Truist - Yahoo Finance
William Blair Downgrades Incyte (BMV:INCY) - Nasdaq
Incyte EVP Barry Flannelly sells $1.34 million in stock By Investing.com - Investing.com South Africa
William Blair Downgrades Incyte (BIT:1INCY) - Nasdaq
Incyte: Still A 'Buy' Despite HS Treatment Data With Povorcitinib (NASDAQ:INCY) - Seeking Alpha
Marginal Zone Lymphoma Pipeline 2025: MOA and ROA Insights, - openPR
INCY Stock Down on Disappointing Skin Disease Study Data - Yahoo Finance
Incyte stock price target cut to $72 at Truist Securities - Investing.com India
This PepsiCo Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga
Incyte’s JAK1 blocker meets goals in Phase III trials - The Pharma Letter
Jefferies cuts Incyte stock price target to $75, keeps Buy rating - Investing.com
Mizuho maintains Incyte stock with $77 target, Neutral rating - Investing.com
Incyte divulges new MRGPRX2 antagonists - BioWorld Online
Citi maintains Buy on Incyte shares, reiterates $88 target - Investing.com
William Blair cuts Incyte stock rating post-trial results - Investing.com
Guggenheim Downgrades Incyte to Neutral From Buy -March 18, 2025 at 06:41 am EDT - Marketscreener.com
Analyst recommendations: Block, Incyte, Ralph Lauren, Five Below, Tesla... - Marketscreener.com
Deutsche Bank Adjusts Price Target on Incyte to $60 From $70, Keeps Hold Rating -March 18, 2025 at 05:50 am EDT - Marketscreener.com
Jefferies Adjusts Price Target on Incyte to $75 From $81, Keeps Buy Rating -March 18, 2025 at 05:50 am EDT - Marketscreener.com
Truist Securities Adjusts Price Target on Incyte to $72 From $74, Keeps Hold Rating -March 18, 2025 at 05:45 am EDT - Marketscreener.com
Incyte Corporation (INCY): Among the Best Biotech Stocks to Buy According to Billionaires - Insider Monkey
William Blair Downgrades Incyte (INCY) to Market Perform - StreetInsider.com
Incyte stock dives after drug trial disappoints investors - Yahoo Finance
Incyte Corp. stock underperforms Monday when compared to competitors - MarketWatch
RBC maintains Incyte stock with $68 target post-data release By Investing.com - Investing.com Australia
Incyte stock tumbles despite meeting main goal in skin disease treatment trial - MSN
Incyte (INCY) Stock Drops on Phase Three Trial Data - GuruFocus.com
Why Incyte (INCY) Stock Is Nosediving - MSN
Leerink says Incyte’s povo trial results disappoint, drug likely to be approved - TipRanks
Oil pressures, Robinhood, Incyte: Market Minute - Yahoo Finance
Top Midday Decliners -March 17, 2025 at 02:00 pm EDT - Marketscreener.com
Incyte Reports Positive Results From Skin Therapy Study; Wells Fargo Cuts Price Target; Shares Drop - Marketscreener.com
Mizuho Reiterates Neutral Rating on Incyte (INCY) - StreetInsider.com
US MARKET Live, 17 March 2025: Incyte Corp, Tesla, and Dollar General among top losers on S&P 500 - Moneycontrol
Incyte stock hit by 11% despite paediatric dermatology trials hitting target - Yahoo Finance
Incyte Leads S&P 500 Decliners on Skin Condition Drug Trial Results - MSN
Incyte stock hit 11% despite paediatric dermatology trials hitting target - Clinical Trials Arena
Incyte Leads S&P 500 Decliners Amidst Phase III Results of PovorcitinibNews and Statistics - IndexBox, Inc.
Top Stock Movers Now: Intel, Netflix, Incyte, and More - Yahoo Finance
Incyte Is Today’s Worst S&P 500 Stock. Here’s Why. - MSN
인사이트 코퍼레이션 (INCY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
0.34%
자본화:
|
볼륨(24시간):